arrow
N

Narek Shaverdian

memorial sloan kettering cancer center
H指数:28
被引数:4,702
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial

不可切除的III期非小细胞肺癌中,Canakinumab联合化放疗和Durvalumab巩固治疗:CHORUS I/II期试验

2026-09-070
OAAI
Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy

KRAS G12C抑制剂的联合胸部放射治疗安全性特征

2026-03-310
PRE
Prospective validation of a pretreatment 18F-FDG PET/CT and mean lung dose model for early radiation pneumonitis

前瞻性验证一种治疗前18F-FDG PET/CT和平均肺剂量模型用于早期放射性肺炎

2025-09-270
OAAI
Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival

非小细胞肺癌患者新辅助化免疫治疗的实际结果:手术、病理完全缓解和事件无进展生存的预测因素

Cancer
IF5.1
2025-09-090
PRE
Stereotactic Body Radiation Therapy for Stage IIA to IIIA Inoperable Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation Trial
2024-07-012
PRE
40 Gray in 5 Fractions for Salvage Reirradiation of Spine Lesions Previously Treated With Stereotactic Body Radiotherapy
2024-03-080
PRE
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapyto Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

寡进展性乳腺癌或非小细胞肺癌患者接受或不接受立体定向全身放疗的标准治疗 (巩固使用放射疗法阻断 [遏制] 寡进展): 一项开放标签,随机,对照,2期研究

LANCET
IF88.5
2024-01-0162
OAAI
ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy

基于ctDNA的I-III期非小细胞肺癌根治性放疗患者分子残留病变检测

2023-09-1910
OAAI
Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer

iSABR的安全性和有效性结果,一项立体定向消融放疗联合Durvalumab治疗早期医学上不能手术的非小细胞肺癌的1期研究

2023-09-0114
PRE
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis
2023-08-0110
OAAI
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

TMB/PD-L1表达和肺炎对III期NSCLC放化疗和durvalumab反应的影响

2023-07-1511
OAAI